Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR

Qiumei Yao, Yinlei Bai, Shaji Kumar, Elaine Au, Alberto Orfao, Chor Sang Chim

Research output: Contribution to journalArticlepeer-review

Abstract

Here we compared clonotype identification by allele-specific oligonucleotide real-time quantitative-PCR (ASO RQ-PCR) and next-generation sequencing (NGS) in 80 multiple myeloma patients. ASO RQ-PCR was applicable in 49/55 (89%) and NGS in 62/78 (80%). Clonotypes identified by both methods were identical in 33/35 (94%). Sensitivity of 10−5 was confirmed in 28/29 (96%) by NGS while sensitivity of RQ-PCR was 10−5 in 7 (24%), 5 × 10−5 in 15 (52%), and 10−4 in 7 (24%). Among 14 samples quantifiable by ASO RQ-PCR, NGS yielded comparable results in 12 (86%). Applicability of NGS can be improved if immunoglobulin heavy-chain incomplete DJ primers are included.

Original languageEnglish (US)
Article number611021
JournalFrontiers in Oncology
Volume10
DOIs
StatePublished - Jan 29 2021

Keywords

  • allele-specific oligonucleotide real-time quantitative-PCR
  • minimal residual disease
  • multiple myeloma
  • next-generation sequencing
  • sensitivity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR'. Together they form a unique fingerprint.

Cite this